IMO 8400

Drug Profile

IMO 8400

Alternative Names: IMO-8400

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator Idera Pharmaceuticals
  • Class Antisense oligonucleotides; Immunotherapies
  • Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 8 antagonists; Toll-like receptor 9 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Waldenstrom's macroglobulinaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dermatomyositis
  • Suspended Diffuse large B cell lymphoma; Waldenstrom's macroglobulinaemia
  • No development reported Graft-versus-host disease; Systemic lupus erythematosus
  • Discontinued Duchenne muscular dystrophy; Plaque psoriasis

Most Recent Events

  • 01 Dec 2016 Idera Pharmaceuticals completes a phase I/II trial in Diffuse large B cell lymphoma (Second-line therapy or greater) in USA (SC) (NCT02252146)
  • 01 Dec 2016 Idera Pharmaceuticals completes a phase I/II trial in Waldenstrom's macroglobulinaemia (Second-line therapy or greater) in USA (NCT02363439)
  • 26 Sep 2016 Suspended - Phase-I/II for Diffuse large B cell lymphoma (Second-line therapy or greater) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top